Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad K Porter

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
The Journal of Infectious Diseases|May 26, 2017
Prophylactic Efficacy of Hyperimmune Bovine Colostral Antiadhesin Antibodies Against Enterotoxigenic Escherichia coli Diarrhea: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 TrialStephen J Savarino, Robin McKenzie, David R Tribble, et al.
Gastroenterology|March 14, 2020
Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before DiagnosisJoana Torres, Francesca Petralia, Takahiro Sato, et al.
Plos One|December 2, 2020
Refinement of the CS6-expressing enterotoxigenic Escherichia coli strain B7A human challenge model: A randomized trialKawsar R Talaat, Chad K Porter, Kayla M Jaep, et al.
Vaccine|September 26, 2020
A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic Escherichia coli fimbrial tip adhesin with heat-labile enterotoxin with mutation R192GMark S Riddle, Milton Maciel, Chad K Porter, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 11, 2013
Lack of homologous protection against Campylobacter jejuni CG8421 in a human challenge modelBeth D Kirkpatrick, Caroline E Lyon, Chad K Porter, et al.
Clinical Trials (London, England)|October 28, 2021
A site assessment tool for inpatient controlled human infection models for enteric disease pathogensChad K Porter, Katherine J Detizio, Nicole Maier, et al.
Lancet Regional Health. Americas|November 7, 2024
Clinical and functional assessment of SARS-CoV-2 sequelae among young marines - a panel studyChad K Porter, Charmagne G Beckett, Elizabeth Cooper, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2018
Enterotoxigenic <i>E. coli</i> virulence gene regulation in human infectionsAlexander A Crofts, Simone M Giovanetti, Erica J Rubin, et al.
Ebiomedicine|April 4, 2021
Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccineKristen A Clarkson, Kawsar R Talaat, Cristina Alaimo, et al.
Mbio|December 12, 2023
Gut microbiome and antibiotic resistance effects during travelers' diarrhea treatment and preventionKevin S Blake, Drew J Schwartz, Srinand Paruthiyil, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
The Journal of Infectious Diseases|May 26, 2017
Prophylactic Efficacy of Hyperimmune Bovine Colostral Antiadhesin Antibodies Against Enterotoxigenic Escherichia coli Diarrhea: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 TrialStephen J Savarino, Robin McKenzie, David R Tribble, et al.
Gastroenterology|March 14, 2020
Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before DiagnosisJoana Torres, Francesca Petralia, Takahiro Sato, et al.
Plos One|December 2, 2020
Refinement of the CS6-expressing enterotoxigenic Escherichia coli strain B7A human challenge model: A randomized trialKawsar R Talaat, Chad K Porter, Kayla M Jaep, et al.
Vaccine|September 26, 2020
A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic Escherichia coli fimbrial tip adhesin with heat-labile enterotoxin with mutation R192GMark S Riddle, Milton Maciel, Chad K Porter, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 11, 2013
Lack of homologous protection against Campylobacter jejuni CG8421 in a human challenge modelBeth D Kirkpatrick, Caroline E Lyon, Chad K Porter, et al.
Clinical Trials (London, England)|October 28, 2021
A site assessment tool for inpatient controlled human infection models for enteric disease pathogensChad K Porter, Katherine J Detizio, Nicole Maier, et al.
Lancet Regional Health. Americas|November 7, 2024
Clinical and functional assessment of SARS-CoV-2 sequelae among young marines - a panel studyChad K Porter, Charmagne G Beckett, Elizabeth Cooper, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2018
Enterotoxigenic <i>E. coli</i> virulence gene regulation in human infectionsAlexander A Crofts, Simone M Giovanetti, Erica J Rubin, et al.
Ebiomedicine|April 4, 2021
Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccineKristen A Clarkson, Kawsar R Talaat, Cristina Alaimo, et al.
Mbio|December 12, 2023
Gut microbiome and antibiotic resistance effects during travelers' diarrhea treatment and preventionKevin S Blake, Drew J Schwartz, Srinand Paruthiyil, et al.
Pageof 13